Critical care of the obese and bariatric surgical patient

Critical Care Clinics

Volumn 19, Issue 1, 2003, Pages 11-32

  Levi, Daniela ^a   Goodman, Elliot R ^a   Patel, Mayank ^b   Savransky, Yevgeny ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPHYLLINE; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ATRACURIUM; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CEPHALOSPORIN DERIVATIVE; DIGOXIN; FENTANYL; FIBRINOLYTIC AGENT; FLUCONAZOLE; HEPARIN; HYDROCORTISONE; LIDOCAINE; LORAZEPAM; LOW MOLECULAR WEIGHT HEPARIN; MIDAZOLAM; MORPHINE; PENICILLIN DERIVATIVE; PHENYTOIN; PROCAINAMIDE; PROPOFOL; REMIFENTANIL; SEDATIVE AGENT; SUXAMETHONIUM; UNINDEXED DRUG; VANCOMYCIN; VERAPAMIL;

ANESTHESIA; ATHEROGENESIS; BARIATRIC SURGERY; BODY MASS; CARCINOGENESIS; CRITICAL ILLNESS; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM ULCER; DISEASE PREDISPOSITION; HEART ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; INFECTION SENSITIVITY; INTENSIVE CARE; LUNG EMBOLISM; METABOLISM; MORTALITY; NUTRITION; OBESITY; PATHOPHYSIOLOGY; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PREDICTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SAFETY; SCORING SYSTEM; SEPSIS; SUDDEN DEATH; SURGICAL PATIENT; SURGICAL RISK; SURGICAL TECHNIQUE; THROMBOGENESIS; TREATMENT INDICATION; VASCULAR ACCESS;

BILIOPANCREATIC DIVERSION; CRITICAL CARE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; GASTRIC BYPASS; GASTROPLASTY; HUMANS; INTUBATION, INTRATRACHEAL; JEJUNOILEAL BYPASS; OBESITY, MORBID; PULMONARY EMBOLISM; TRIAGE; VENOUS THROMBOSIS;

EID: 0037233241     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0704(02)00060-X     Document Type: Review

References (106)

1. National Institutes of Health Consensus Development Conference Panel. Gastrointestinal surgery for severe obesity. Ann Intern Med 1991;115:956-61.
2. Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341:1097-105.
3. El-Solh A, Sikka P, Bozkanat E, et al. Morbid obesity in the medical ICU. Chest 2001;120:1989-97.
4. Adami GF, Ravera G, Marinari GM, et al. Metabolic syndrome in severely obese patients. Obesity Surgery 2001;11(5):543-5.
5. Friedman JB. Obesity in the new millennium. Nature 2000;404:632-4.
6. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
7. Smith AI, Funder JW. Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues. Endocr Rev 1988;9:159-79.
8. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 1999;130:670-80.
9. Geloneze B, Tambascia MA, Pareja JC, et al. Serum leptin levels after bariatric surgery across a range of glucose tolerance from normal to diabetes. Obes Surg 2001;11:693-8.
10. Marinari GM, Scopinaro N, Adami GF. Leptin and HDL-cholesterol in non-diabetic normotensive subjects. Obes Surg 2001;11:252-3.
11. Maruna PG, Gurlich R, Fried M, et al. Leptin as an acute phase reactant after non-adjustable laparoscopic gastric banding. Obes Surg 2001;11:609-14.
12. Meier CA, Bobbioni E, Gabay C, et al. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab 2002;87(3):1184-8.
13. Gabay C, Dreyer MG, Pellegrinelli N, et al. Leptin directly induces the secretion of interleukin-1 receptor antagonist in human monocytes. J Clin Endocrinol Metab 2001;86:783-91.
14. Gabay C, Smith MF, Eidlen D, et al. Interleukin-1 receptor antagonist is an acute-phase protein. J Clin Invest 1997;99:2930-40.
15. Orban Z, Remaley AT, Sampson M, et al. The differential effect of food intake and beta-adrenergic stimulation on adipose-derived hormones and cytokines in man. J Clin Endocrino Metab 1999;84:2126-33.
16. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Sleep apnea and daytime sleepiness and fatigue: relations with visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000;85:1151-8.
17. Cottam DR, Schaefer PA, Fahmy D, et al. The effect of obesity on neutrophil Fc receptors and adhesion molecules (CD16, CD11b, CD62L). Obes Surg 2001;12:230-5.
18. Juhan-Vague MCA. Regulation of fibrinolysis in the development of atherothrombosis: role of adipose tissue. Throm Haemost 1999;82:832-6.
19. Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetes patients. Diabetes 1993;42:1-7.
20. Hori Y, Gabazza EC, Yano Y, et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87(2):660-5.
21. Sugerman HJ, et al. Gastric surgery for respiratory insufficiency of obesity. Chest 1986;90:82-91.
22. Greco AV, Mingrone G, Giancaterini A, et al. Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes 2002;51(1):144-51.
23. Alpert MA, Terry BF, Hamm CR, et al. Effect of weight loss on the ECG of normotensive morbidly obese patients. Chest 2001;119:507-10.
24. Kanoupakis E, Michaloudis D, Fraidakis O, et al. Left ventricular function and cardiopulmonary performance following surgical treatment of morbid obesity. Obes Surg 2001;11:552-8.
25. Scopinaro N, Gianetta E, Adami GF, et al. Biliopancreatic diversion for obesity at eighteen years. Surgery 1996;119(3):261-8.
26. Balsiger BM, Poggio JL, Mai J. Ten and more years after vertical banded gastroplasty as primary operation for morbid obesity. J Gastrointest Surg 2000;4(6):598-605.
27. Kuzmak LI, Yap IS, McGuire L, et al. Surgery for morbid obesity. Using an inflatable gastric band. AORN J 1990;51(5):1307-24.
28. Mason EE. Gastric bypass in obesity. Surg Clin North Am 1967;47:1345-54.
29. Mason EE. Optimizing results of gastric bypass. Ann Surg 1975;182:405-15.
30. Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 2000;232(4):515-29.
31. Sugerman HJ, Starkey J, Birkenhauer R. A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets vs. nonsweets eaters. Ann Surg 1987;205:613-24.
32. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995;222:339-59.
33. Sugerman HJ, Kellum JM, Engle KM. Gastric bypass for treating severe obesity. Am J Clin Nutr 1992;55:560s-6s.
34. Brolin R. Gastric bypass. Surgical Clin North Am 2001;81(5):1077-95.
35. Brodsky JB. Morbid obesity and tracheal intubation. Anesth Analg 2002;94(3):732-6.
36. Brolin R. Complications of surgery for severe obesity. Prob Gen Surg 2000;17:55-61.
37. Mason EE. Gallbladder management in obesity surgery. Obesity Surgery 2002;12:222-9.
38. DeMaria EJ, Sugerman HJ, Meador JG, et al. High failure rate after laparoscopic adjustable silicone gastric banding for treatment of morbid obesity. Ann Surg Jun 2001;233(6):809-18.
39. Menes T. Laparoscopy: searching for the proper insufflation gas. Surg Endosc 2000;14(11):1050-6.
40. Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y-500 patients: technique and results with 3-60-month follow-up. Obes Surg 2000;10:233-9.
41. Davidson JE, Callery C. Care of the obesity surgery patient requiring immediate-level care or intensive care. Obes Surg 2001;11:93-7.
42. Gniuli D, Liverani E, Greco AV, et al. Glucose disposal in morbidly obese patients in the early post-operative period. Obes Surg 2001;11:686-92.
43. Hajzman Z, Kabelac K, Kaska M, et al. Gastric banding: intraoperative and early postoperative complications and their prevention. Obes Surg 2001;11:220-2.
44. Sugerman HJ, Sugerman EL, Wolfe L, et al. Risks and benefits of gastric bypass in morbidly obese patients with severe venous stasis disease. Ann Surgery 2001;234(1):41-6.
45. Williamson JA, Webb RK, Szekely S, et al. The Australian incident monitoring study: difficult intubation: an analysis of 2,000 incident reports. Anaesth Intensive Care 1993;21:602-7.
46. Levitan R, Ochroch EA. Airway management and direct laryngoscopy - a review and update. Crit Care Clin 2000;16(3):373-88.
47. Keller C. The laryngeal mask airway ProSeal(TM) as a temporary ventilatory device in grossly and morbidly obese patients before laryngoscope-guided tracheal intubation. Anesth Analg 2002;94(3):737-40.
48. Ovassapian A. The flexible bronchoscope: a tool for anesthesiologists. Clin Chest Med 2001;22(2):281-99.
49. Fuso L, Cisternino L, Di Napoli A, et al. Role of spirometric and arterial gas data in predicting pulmonary complications after abdominal surgery. Respir Med 2000;94(12):1171-6.
50. Sugerman HJ. Gastric surgery for morbid obesity. In: Zinner MJ, Maingot S, editors. Abdominal operations. 10th edition. Stamford (CT): Appleton & Lange; 1997. p. 1057-79.
51. Sugerman HJ. Bariatric surgery for severe obesity. J Assoc Acad Minor Phys 2001;12(3):129-36.
52. Pelosi P, Croci M, Ravagnan I, et al. Total respiratory system, lung, and chest wall mechanics in sedated-paralyzed postoperative morbidly obese patients. Chest 1996;109:144-51.
53. Pelosi P, Ravagnan I, Giurati G, et al. Positive end-expiratory pressure improves respiratory function in obese but not in normal subjects during anesthesia and paralysis. Anesthes 1999;(91)5:1221-31.
54. Perilli V, Sollazzi L, Bozza P, et al. The effects of the reverse Trendelenburg position on respiratory mechanics and blood gases in morbidly obese patients during bariatric surgery. Anesth Analg 2000;91(6):1520-5.
55. Marik P, Varon J. The obese patient in the ICU. Chest 1998;113(2):492-8.
56. Torrington KG, Sorenson DE, Sherwood LM. Postoperative chest percussion with postural drainage in obese patients following gastric stapling. Chest 1984;86:891-5.
57. Clagett GP, Anderson Jr FA, Heit J, et al. Prevention of venous thromboembolism. Chest 1995;108(Suppl):312s-34s.
58. Clagett GP, Anderson FA, Geets W, et al. Prevention of venous thromboembolism. Chest 1998;114(Suppl 5):531s-60s.
59. Merli GJ. Prophylaxis for deep venous thrombosis and pulmonary embolism in the surgical patient. Clin Cornerstone 2000;2(4):15-28.
60. Wu EC. Current practices in the prophylaxis of venous thromboembolism in bariatric surgery. Obes Surg 2000;10(1):7-13.
61. Goodman E, Veith FJ, Ohki T, et al. Strategic methods for prophylactic IVC filter placement during roux-en-y gastric bypass surgery reduce the incidence of pulmonary embolism. To be presented at ASBS June 24-9, 2002.
62. MacGregor MI. Topics in clinical medicine: serious complications and sudden death in the "Pickwickian syndrome". Hopkins Medical Journal 1970;189:279-95.
63. Sugerman HJ, et al. Long-term effects of gastric surgery for treating respiratory insufficiency of obesity. Am J Clin Nutr 1992;55(Suppl):597s-601s.
64. Capan LM, Miller SM. Monitoring for suspected pulmonary embolism. Anesth Clin N America 2001;19(4):673-703.
65. Alexander JK. The cardiomyopathy of obesity. Prog Cardiovasc Dis 1985;27:325-34.
66. Alexander JK, Dennis EW, Smith WH, et al. Blood volume, cardiac output and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull 1962;1:39-44.
67. De Vitiis O, Fazio S, Peleto M, et al. Obesity and cardiac function. Circulation 1981;64:477-80.
68. Messerli FH. Cardiovascular effects of obesity and hypertension. Lancet 1982;1:1165-8.
69. Alport MA, Hashimi MW. Obesity and the heart. Am J Med Sci 1993;306:117-23.
70. Alport MA, Lambert CR, Tarry BE, et al. Influence of left ventricular mass on left ventricular diastolic filling in normotensive morbid obesity. Am Heart J 1995;130:1068-73.
71. Backman L, Freyschuss U, Hallberg D, et al. Cardiovascular function in extreme obesity. Acta Med Scand 1973;193:437-46.
72. Bernard RW, Stahl WM. Subclavian vein catheterization: a prospective study. Ann Surg 1971;173:184-90.
73. Sznajder JI, Bitterman H, Weiner P, et al. Central vein catheterization: failure and complication rates by three percutaneous approaches. Arch Interm Med 1986;146:259-61.
74. Randolph AG, Cook DJ, Gonzales CA, et al. Ultrasound guidance for placement of central venous catheters. Crit Care Med 1996;24:2053-8.
75. Zengin K, Taskin M, Sakoglu N, et al. Systemic inflammatory response after laparoscopic and open application of adjustable banding for morbidly obese patients. Obes Surg 2002;12:276-9.
76. Buckwalter JA, Herbst Jr CA. Leaks occurring after gastric bariatric operations. Surgery 1988;103:156-60.
77. Mason EE, Doherty C, Maher JW, et al. Superobesity and gastric reduction procedures. Gastroenteral Clin North Am 1987;16:495-502.
78. Deitch EA, Goodman ER. Prevention of multiple organ failure. Surg Clin N Amer 1999;79(6):1471-88.
79. Ganci-Cerrud G, Herrera MF. Role of radiologic contrast studies in the early postoperative period after bariatric surgery. Obesity Surgery 1999;9(6):532-4.
80. Serafini FM, Anderson WM, Ghassemi P, et al. The utility of contrast studies and drains in the management of patients after roux-en-y gastric bypass. Obes Surg 2001;12:34-8.
81. Cuthbertson DP. The distribution of nitrogen and sulphur in the urine during conditions of increased catabolism. J Biochem 1931;25:236-44.
82. Schauer PR, Sirinek KR. The laparoscopic approach reduces the endocrine response to elective cholecystectomy. Am Surg 1995;61:106-11.
83. Jeevanandam M, Young DH, Schiller WR. Obesity and the metabolic response to severe multiple trauma in man. J Clin Invest 1991;87:262-9.
84. Burge JC, Goon A, Choban PS, et al. Efficacy of hypocaloric total parenteral nutrition in hospitalized obese patients: a prospective, double-blind randomized trial. Parenter Enteral Nutr 1994;18:203-7.
85. Brown G, Dodeck P. Intravenous insulin nomogram improves blood glucose control in the critically ill. Critical Care Med 2001;29(9):1714-9.
86. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000;39(3):215-31.
87. Kotlyar M. Effects of obesity on the cytochrome P450 enzymes. Int J Clin Pharmacol Ther 1999;37(1):8-19.
88. Watson AM. Effect of leptin on cytochrome P450, conjugation, and antioxidant enzymes in the ob/ob mouse. Drug Metab Dispos 1999;27(6):695-700.
89. Gholam PM. Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obesity Surgery 2002;12(1):49-51.
90. Bearden DT, Rodvold KA. Dosage adjustment for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacol 2000;38(5):415-26.
91. Cohen LG, Di Biasio A, Lisco SJ, et al. Fluconazole serum concentrations and pharmacokinetics in an obese patient. Pharmacotherapy 1997;17(5):1023-6.
92. Pittrow L, Penk A. Special pharmacokinetics of fluconazole in septic, obese and burn patients. Mycoses 1999;42(Suppl 2):87-90.
93. Spruill WJ, Wade WE, Huckaby WG, et al. Achievement of anticoagulation by using a weight-based heparin dosing protocol for obese and nonobese patients. Am J Health-System Pharmacy 2001;58(22):2143-6.
94. Yee JY, Duffull SB. The effect of body weight on dalteparin pharmacokinetics. Eur J Clin Pharm 2000;56(4):293-7.
95. Lottenberg SA, Giannella-Neto D, Derendorf H, et al. Effect of fat distribution on the pharmakoinetics of cortisol in obesity. Int J Pharmacol Ther 1998;36(9):501-5.
96. Gorski JC, Jones DR, Haehner-Daniels BD, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998;64:133-43.
97. Hamaoka N, Oda Y, Hasel I, et al. Propofol decreases the clearance of midazolam by inhibiting the CYP3A4: an in vivo and in vitro study. Clin Pharmacol Ther 1999;66:110-7.
98. Bailie GR, Cockshott ID, Douglas EJ, et al. Pharmacokinetics of propofol during and after long-term continuous infusion for maintenance of sedation in ICU patients. Br J Anaesth 1992;68:486-91.
99. Grossman M, Abiose A, Tangphao A, et al. Morphine-induced venodilatation in humans. Clin Pharmacol Ther 1996;60:554-60.
100. Egan TD, Huizinga B, Gupta SK, et al. Remifentanyl pharmacokinetics in obese versus lean patients. Anesthesiology 1998;89(3):562-73.
101. Varon J, Marik P. Management of the obese critically ill patient. Crit Care Clin 2001;17(1):187-200.
102. Barie PS, Hydo LJ, Fischer E. Utility of illness severity scoring for prediction of prolonged surgical critical care. J Trauma 1996;40(4):513-8; discussion 518-9.
103. Cerra FB, Negro F, Abrams J, et al. APACHE II score does not predict multiple organ failure or mortality in postoperative surgical patients. Arch Surg 1990;125(4):519-22.
104. Kasalicky M, Fried M, Peskova M, et al. Some complications after laparoscopic nonadjustable gastric banding. Obesity Surg 1999;9:443-5.
105. Rutledge R. The mini-gastric bypass: experience with the first 1,274 cases. Obesity Surg 2001;11:276-80.
106. Schauer PR, Ikramuddin S. Laparoscopic surgery for morbid obesity. Surg Clin N Amer 2001;81(5):1145-79.